Insider Trading April 17, 2026 05:28 PM

Faraday Future Co-Global CEO Makes $100 Purchase of Series A Preferred Share

Small, symbolic insider buy comes as company shifts toward early-stage commercialization amid ongoing losses

By Maya Rios FFAI
Faraday Future Co-Global CEO Makes $100 Purchase of Series A Preferred Share
FFAI

Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) Co-Global CEO Matthias Aydt purchased one share of the company's Series A Preferred Stock for $100 on April 15, 2026, according to an SEC Form 4. The move is notable for its symbolic value as the electric vehicle maker works to transition from strategic planning to early commercialization while reporting operating losses and facing a steep decline in its common share price over the past year.

Key Points

  • Matthias Aydt, Co-Global CEO of Faraday Future (NASDAQ: FFAI), purchased one share of Series A Preferred Stock for $100 on April 15, 2026, per an SEC Form 4 filing.
  • Faraday Future reported Q4 2025 results that signal a shift from strategy toward early-stage commercialization, while continuing to record operating losses.
  • The company's common stock has fallen 67.55% over the past year and is trading at $0.30; the firm has a market capitalization of $73.56 million.

Overview

Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) disclosed that Co-Global CEO Matthias Aydt acquired a single share of the company's Series A Preferred Stock at a price of $100 on April 15, 2026. The transaction, documented in a Form 4 filing with the Securities and Exchange Commission, lists the total value of the purchase as $100.00.

Context on market and stock performance

The purchase arrives against a backdrop of pressure on the company's publicly traded common shares. Faraday Future's market capitalization is reported at $73.56 million, and its common stock has fallen 67.55% over the last 12 months, trading at $0.30. The purchase of a single preferred share is described in the filing as a one-share transaction for $100.00 in total value.

Company reporting and strategic shift

In a separate disclosure, Faraday Future reported its fourth-quarter 2025 earnings, which the company framed as evidence of a move from strategic development toward early-stage commercialization. The earnings announcement emphasized strategic developments but did not include specific revenue or net income figures in the report. The company noted it continues to record operating losses, while expressing optimism about its strategic direction and prospects.

Investor reaction

The report states that investors appeared to respond positively ahead of the market open, as indicated by premarket activity following the earnings release. The filing and the earnings update together reflect a period in which Faraday Future is attempting to advance commercialization efforts for its electric vehicle initiatives while managing the financial constraints associated with operating losses.

Additional details and resources

The Form 4 filing documents the transaction as one share purchased at $100.00, totaling $100. InvestingPro users are noted to have access to 18 additional ProTips related to FFAI's financial health and market position. The company's emphasis in its earnings release on strategic shifts highlights an important phase in its evolution from planning toward commercialization, even as specific top-line and bottom-line figures were not disclosed in that report.


Note: The article presents facts from regulatory filings and the company's earnings release without adding financial figures not provided in those documents.

Risks

  • Ongoing operating losses present financial risk to Faraday Future's ability to execute its commercialization strategy - this impacts the electric vehicle and broader automotive capital markets.
  • The lack of disclosed revenue and net income figures in the Q4 2025 earnings release creates uncertainty around near-term financial performance - affecting investors and analysts tracking EV manufacturers.
  • Significant recent decline in the common share price reflects market skepticism and heightens equity financing risk for the company - relevant to equity markets and potential creditors.

More from Insider Trading

OrbiMed Expands Stake in Traws Pharma via Strategic Private Placement Apr 28, 2026 Rexford Industrial Realty General Counsel Completes $1.18 Million Stock Sale Apr 28, 2026 Bicara Therapeutics CMO Executes Rule 10b5-1 Trading Plan Involving Share Sales and Option Exercises Apr 28, 2026 Abbott Laboratories Director Daniel Starks Executes Substantial Open Market Share Purchase Apr 28, 2026 BlackRock President Robert Kapito Executes $9.2 Million Share Sale Apr 28, 2026